13 Best Russell 2000 Stocks to Buy Right Now
On January 6, Royce Investment Partners released their outlook for the small-cap stocks in 2026.
Guardant Health Inc. (GH)
Market is closed
Sector: Services-Medical Laboratories
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Navellier & Associates Louis Navellier | 5,412 | $552,782 | -31% | 0.06% |
| 2. | Bayforest Capital Theodoros Tsagaris | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.82 | 2,187 | $38,962.72 | 12,722 | 2024-03-18 | Filing | |
| $32.78 | 750 | $24,584.25 | 5,193 | 2023-06-09 | Filing | |
| $32.68 | 2,231 | $72,913.77 | 4,443 | 2023-06-09 | Filing | |
| $26.15 | 8,600 | $224,927.84 | 2,049,238 | 2023-03-15 | Filing | |
| $26.33 | 84,452 | $2,223,908.30 | 2,040,638 | 2023-03-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $115.70 | 3,249 | $375,902.15 | 20,990 | 2026-01-21 | Filing | |
| $113.48 | 3,619 | $410,681.59 | 24,239 | 2026-01-21 | Filing | |
| $112.34 | 1,703 | $191,318.09 | 27,858 | 2026-01-21 | Filing | |
| $113.44 | 88 | $9,982.69 | 20,990 | 2026-01-07 | Filing | |
| $112.62 | 3,632 | $409,029.30 | 21,078 | 2026-01-07 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 12,160,768 | $1,242,100,844 | 0.02% | |
| 2. | 4,890,026 | $499,467,256 | 0.42% | |
| 3. | 1,710,169 | $174,676,662 | 0.03% | |
| 4. | 1,170,337 | $119,538,219 | 0.07% | |
| 5. | 57,756,000 | $105,718,512 | 0.83% |
News See All
Strong Results and Improved Guidance Lifted Guardant Health (GH) in Q4
Fred Alger Management, an investment management company, released its “Alger Small Cap Focus Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Analysts Turn More Bullish on Guardant Health, Inc. (GH) as 2026 Growth Catalysts Build
TheFly reported on January 9 that Stifel increased its price target on GH to $120 from $100 while maintaining a Buy rating.
Top 10 Oncology Stocks to Buy Now
The oncology market in the United States was estimated at $81.34 billion in 2025 and is expected to reach $211.78 billion by 2034 with a compound annual growth rate of 11.75%.
Guggenheim Analyst is Bullish on Guardant Health, Inc. (GH)
On January 5, 2026, TheFly reported that Wall Street firms had given Guardant Health, Inc. (NASDAQ:GH) two price target raises.
Canaccord Names Guardant Health (GH) Top Life Science Pick, Cites Strong Growth and Low Downside
Guardant Health Inc. (NASDAQ:GH) is one of the hottest large-cap stocks of 2025.
10 Hottest Large-Cap Stocks of 2025
On December 22, Scott Wren, chief global equity strategist at Wells Fargo Investment Institute, joined CNBC's 'Squawk on the Street' to express optimism regarding accelerating earnings alongside moderating...
Multiple Analysts Lift Guardant Health, Inc. (GH) Targets on Screening and Data Growth
TheFly reported on December 17 that Mizuho analyst Anthony Petrone maintained an Outperform rating on GH and raised the price target to $120 from $100, reflecting growing confidence in the company’...
7 Most Promising Gene Editing Stocks According to Analysts
Gene editing has rapidly evolved into a transformative class of technologies that allow scientists to precisely insert, delete, or modify DNA within living cells.
Hedge Fund Resource Center Billionaire Hedge Funds
